FDA Grants Fast Track Designation for TAR-200 in Muscle-Invasive Bladder Cancer

April 6, 2018 – On April 3, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for TAR-200, a gemcitabine-releasing intravesical system (GemRIS), for the treatment of patients with organ-confined or locally advanced muscle-invasive bladder cancer who are unfit for curative-intent therapy. This designation offers TARIS earlier and more frequent opportunities to collaborate with the FDA to expedite the development and availability of TAR-200 … (leggi tutto)